Zentek and Triera Biosciences receive USD$791,000 from Government of Canada to test multivalent aptamer technology
Zentek has announced that its wholly-owned subsidiary Triera Biosciences has received a CAD$1.1 million (around USD$791,000) Government of Canada contract to test its multivalent aptamer technology for the rapid drug discovery of therapeutics or prophylactics of highly pathogenic avian influenza (“HPAI”) A(H5N1).
Triera was awarded a these funds through Innovation, Science and Economic Development Canada's (“ISED”) Innovative Solutions Canada (“ISC”) program: Health Advanced And Emerging Medical Technologies. Triera’s multivalent aptamer technology was selected for its potential to be used as a rapid drug development platform.